Cost of treatment of metastatic non-small lung cancer in Sweden, 2011–2023
This study highlights the increasing economic burden of mNSCLC treatment in Sweden, driven by the targeted and IO drugs. While ALK-, EGFR-targeted, and IO drugs contribute to high first-year mean costs, IO drug costs decline significantly in subsequent years after diagnosis.
Authors
- Linus Jönsson (ORCID: https://orcid.org/0000-0001-5751-6292)
- Nils Wilking
- Michael Sweeting (ORCID: https://orcid.org/0000-0003-0980-8965)
- Kun Kim (ORCID: https://orcid.org/0000-0003-1587-3325)
Institutions
- Karolinska Institutet (SE)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Sweden) (SE)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-10-26
- DOI
- https://doi.org/10.2340/1651-226x.2025.44650
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52